Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress

Phytotherapy Research

Volumn 23, Issue 12, 2009, Pages 1678-1684

  Comelli, Francesca ^a   Bettoni, Isabella ^a   Colleoni, Mariapia ^b   Giagnoni, Gabriella ^a   Costa, Barbara ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cannabinoid; Cannabis sativa; Diabetes; Nerve growth factor; Neuropathic pain; Oxidative stress

Indexed keywords

ALKANE DERIVATIVE; CANNABICHROMENE; CANNABIDIOL; CANNABIDIOLIC ACID; CANNABIDIVARIN; CANNABIGEROL; CANNABIS; CAROTENOID; GLUTATHIONE; NERVE GROWTH FACTOR; NEUROTROPHIN; SQUALENE; STEROL DERIVATIVE; TERPENE DERIVATIVE; TETRAHYDROCANNABINOL; TOCOPHEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; HYPERGLYCEMIA; LIPID PEROXIDATION; MALE; NEUROPATHIC PAIN; NONHUMAN; OXIDATIVE STRESS; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; CANNABIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; GLUTATHIONE; HYPERALGESIA; HYPERGLYCEMIA; LIPID PEROXIDATION; LIVER; MALE; NERVE GROWTH FACTOR; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, WISTAR; SCIATIC NERVE;

CANNABIS; CANNABIS SATIVA; RATTUS;

EID: 73449084110     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2806     Document Type: Article

References (42)

1. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV. 1996. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2: 703-707.
2. Apfel SC, Schwartz S, Adornato BT et al. 2000. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 284: 2215-2221.
3. Bridges D, Ahmand K, Rice AS. 2001. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133: 586-594.
4. Chen Y, Buck J. 2000. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 293: 807- 812.
5. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B. 2008. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 22: 1017-1024.
6. Costa B, Colleoni M, Conti S et al. 2004a. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369: 294-299.
7. Costa B, Colleoni M, Conti S et al. 2004b. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 141: 4-8.
8. Costa B, Siniscalco D, Trovato AE et al. 2006. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 148: 1022-1032.
9. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. 2007. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556: 75-83.
10. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. 1976. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19: 300-309.
11. Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME. 2004. Cannabinoids block tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 368: 82-86.
12. Feillet-Coudray C, Rock E, Coudray C et al. 1999. Lipid peroxidation and antioxidant status in experimental diabetes. Clin Chim Acta 284: 31-43.
13. Fox A, Eastwood C, Gentry C, Manning D, Urban L. 1999. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 81: 307-316.
14. Fox A, Kesingland A, Gentry C et al. 2001. The role of central and peripheral cannabinoid receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
15. Grassmann J. 2005. Terpenoids as plant antioxidants. Vitam Horm 72: 505-535.
16. Hampson AJ, Grimaldi M, Axelrod J, Wink D. 1998. Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268-8273.
17. Hargreaves KM, Dubner R, Brown F, Flores C, Joris J. 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
18. Hellweg R, Wöhrle M, Hartung HD, Stracke H, Hock C, Federlin K. 1991. Diabetes mellitus-associated decrease in nerve growth factor levels is reversed by allogeneic pancreatic islet transplantation. Neurosci Lett 125: 1-4.
19. Hissin PJ, Hilf R. 1976. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74: 214-226.
20. Karasu C, Dewhurst M, Stevens EJ, Tomlinson DR. 1995. Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids. Diabetologia 38: 129-134.
21. Lever IJ, Rice AS. 2007. Cannabinoids and pain. Handb Exp Pharmacol 177: 265-306.
22. Low PA, Nickander KK, Tritschler HJ. 1997. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46: S38-S42.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
24. Malcangio M, Tomlinson DR. 1998. A pharmacological analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76: 151-157.
25. Malfait AM, Gallily R, Sumariwalla PF et al. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 9561-9566.
26. Martin CL, Albers J, Herman WH et al. 2006. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29: 340-344.
27. Nagamatsu M, Nickander KK, Schmelzer JD et al. 1995. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18: 1160-1167.
28. Nakamura J, Kato K, Hamada Y et al. 1999. A protein kinase Cbeta-selective inhibitor ameliorates neural dysfunction in streptozotocin- induced diabetic rats. Diabetes 48: 2090-2095.
29. Navarro X, Kennedy WR. 1991. Evaluation of thermal and pain sensitivity in type I diabetic patients. J Neurol Neurosurg Psychiatry 54: 60-64.
30. Norrsell U, Eliasson B, Frizell M, Wallin BG, Wesslau C, Olausson H. 2001. Tactile directional sensibility and diabetic neuropathy. Muscle Nerve 24: 1496-1502.
31. Ohkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358.
32. Pertwee RG. 2006. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30: S13-S18.
33. Pittenger G, Vinik A. 2003. Nerve growth factor and diabetic neuropathy. Exp Diabesity Res 4: 271-285.
34. Pop-Busui R, Sima A, Stevens M. 2006. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 22: 257-273.
35. Romero FJ, Martínez-Blasco A, Bosch-Morell F, Marín N, Trenor C, Romá J. 1999. Glycemic control and not protein kinase C inhibition prevents the early decrease of glutathione peroxidase activity in peripheral nerve of diabetic mice. J Peripher Nerv Syst 4: 265-269.
36. Szallasi A, Cortright DN, Blum CA, Eid SR. 2007. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6: 357-371.
37. Tomlinson DR, Fernyhough P, Diemel LT. 1997. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 46: S43-S49.
38. Ulugol A, Karadag HC, Ipci Y, Tamer M, Dokmeci I. 2004. The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 371: 167-170.
39. Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
40. Yilmaz HR, Uz E, Yucel N, Altuntas I, Ozcelik N. 2004. Protective effect of caffeic acid phenethyl ester (CAPE) on lipid peroxidation and antioxidant enzymes in diabetic rat liver. J Biochem Mol Toxicol 18: 234-238.
41. Zimmermann M. 1983. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.
42. Zochodne DW. 1999. Diabetic neuropathies: features and mechanisms. Brain Pathol 9: 369-391.